Certara, Inc. has appointed Faiz Mohammed as Interim Chief Financial Officer, effective July 14, 2026, following the resignation of Chief Financial Officer John Gallagher. The company has affirmed its 2026 financial guidance, keeping projections unchanged from the initial outlook provided during the first quarter earnings call on May 11, 2026. Certara has engaged a leading executive search firm to identify a permanent successor to the CFO role.

Management Transition Details

Mr. Mohammed, Senior Vice President of Finance and Treasurer, has served as a finance leader with Certara since 2018. He brings more than 25 years of senior finance and accounting experience across public and private equity-backed companies to the interim role.

Certara operates as a global leader in model-informed drug development, transforming drug discovery and development by assisting scientists and clinical teams in generating regulatory-grade evidence faster. Its solutions integrate biosimulation, clinical intelligence, and regulatory science into the workflows of drug developers worldwide. The company's client base includes more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies.

The Schall Law Firm, a national shareholder rights litigation firm, announced it is investigating Certara for potential violations of federal securities laws. The investigation focuses on whether the company issued false or misleading statements or failed to disclose pertinent information to investors. This legal scrutiny follows a significant drop in Certara's share price after the release of its financial results.

Certara reported its Q1 2026 financial results on May 11, 2026, revealing a decline in services revenues and bookings. The company attributed the performance to "softer performance from Tier 1 customers in MIDD services." Following this announcement, shares of Certara fell by 19% on the same day, prompting the review of potential investor claims.

The firm is examining whether Certara's disclosures regarding its business performance and outlook were accurate and compliant with securities regulations. The investigation aims to determine if investors were misled by the company's public statements prior to the stock price decline.

Investors who suffered losses in Certara are encouraged to participate in the investigation. Brian Schall of The Schall Law Firm is available to discuss investor rights free of charge. The firm specializes in securities class action lawsuits and represents investors globally.